ATLANTA, Oct. 14, 2022 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical firm aiming to meet ladies’s wants worldwide by creating a collection of product candidates that embrace minimally invasive, in-office applied sciences for reproductive well being, right now introduced that the Company’s administration crew will likely be attending the 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress to be held in Anaheim, California from October 22-26, 2022.
Members of the administration crew will likely be showcasing its applied sciences, together with FemaSeed® and FemVue®, at its sales space #1011.
About Femasys
Femasys Inc. is a biomedical firm aiming to meet ladies’s wants worldwide by creating a collection of product candidates that embrace minimally invasive, in-office applied sciences for reproductive well being. Its two lead product candidates are FemBloc® everlasting contraception and FemaSeed® localized directional insemination for infertility. The Company’s product for fallopian tube evaluation by ultrasound, FemVue®, and FemCerv®, an endocervical tissue sampler are at present being marketed in the United States. Femasys can be advancing FemCath™, an intrauterine catheter for selective analysis of the fallopian tubes supposed to be marketed alongside its different women-specific medical merchandise in the doctor’s workplace setting. To be taught extra, go to www.femasys.com or observe us on Twitter and LinkedIn.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
[email protected]
Media
Karissa Cross, Ph.D.
LifeSci Communications
[email protected]
Femasys Inc.
Investor Contact:
[email protected]
Media Contact:
[email protected]
